Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06100991 · ClinicalTrials.gov registry record
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
A clinical trial of Generalized Pustular Psoriasis, sponsored by CorEvitas.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06100991: Recruiting study of Generalized Pustular Psoriasis, sponsored by CorEvitas.
NCT06100991 is a study of Generalized Pustular Psoriasis that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 200 participants, above the 99-participant average among 3 other Generalized Pustular Psoriasis trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06100991, a study of Generalized Pustular Psoriasis, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target
Primary Outcome
The major clinical outcomes include an assessment of the epidemiology of GPP; to better understand the presentation and natural history.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas, LLC - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2099-12 |
What NCT06100991 shows while recruiting
NCT06100991 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 99-participant average among 3 other Generalized Pustular Psoriasis trials with a reported enrollment target (102% higher).
The record links to 1 condition, with Generalized Pustular Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT06100991 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06100991 about?
NCT06100991 is a clinical study titled "CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry". Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target
What is the current status of trial NCT06100991?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-09-19. Estimated completion is 2099-12.
What conditions does trial NCT06100991 study?
This clinical trial studies the following conditions: Generalized Pustular Psoriasis.
Who is sponsoring clinical trial NCT06100991?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06100991 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Pustular Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI